| US 7,579,488 B2 | ||
| Vitamin D receptor modulators | ||
| Jianliang Lu, Fishers, Ind. (US); Tianwei Ma, Carmel, Ind. (US); Sunil Nagpal, Carmel, Ind. (US); Quanrong Shen, Fishers, Ind. (US); Alan M. Warshawsky, Carmel, Ind. (US); Jason Matthew Ochoada, Greenwood, Ind. (US); and Ying Kwong Yee, Carmel, Ind. (US) | ||
| Assigned to Eli Lilly and Company, Indianapolis, Ind. (US) | ||
| Appl. No. 10/579,563 PCT Filed Nov. 16, 2004, PCT No. PCT/US2004/035529 § 371(c)(1), (2), (4) Date May 12, 2006, PCT Pub. No. WO2005/051938, PCT Pub. Date Jun. 09, 2005. |
||
| Claims priority of provisional application 60/523905, filed on Nov. 20, 2003. | ||
| Prior Publication US 2007/0106095 A1, May 10, 2007 | ||
| Int. Cl. C07D 307/87 (2006.01); C07D 307/00 (2006.01) | ||
| U.S. Cl. 549—462 | 17 Claims |
1. A compound represented by a formula below:
 R and R′ are independently C1-C5 alkyl, or together R and R′ form a saturated carbocyclic ring having from 3 to 8 carbon atoms;
RP3 is hydrogen or C1-C5 alkyl;
(LP2) is
 ZP is a branched C3-C5 alkyl;
ZFB is attached to the 5 or 6 position on the benzofuranyl ring and selected from:
—CO2H
—CO2(C1-C5 alkyl),
—C(O)NMe2,
—CO2(C1-C5 alkyl)-NH2,
—C(O)NH—CH2—C(O)OH,
—C(O)NH—CH2—C(O)OMe,
—C(O)NH—CH2—C(O)OEt,
—C(O)NH—CH2—C(O)OiPr,
—C(O)NH—CH2—C(O)OtBu,
—C(O)NH—CH(Me)-C(O)OH,
—C(O)NH—CH(Me)-C(O)OMe,
—C(O)NH—CH(Me)-C(O)OEt,
—C(O)NH—CH(Me)-C(O)iPr,
—C(O)NH—CH(Me)-C(O)tBu,
—C(O)NH—CH(Et)-C(O)OH,
—C(O)NH—C(Me)2-C(O)OH,
—C(O)NH—C(Me)2-C(O)OMe,
—C(O)NH—C(Me)2-C(O)OEt,
—C(O)NH—C(Me)2-C(O)iPr,
—C(O)NH—C(Me)2-C(O)tBu,
—C(O)NH-CMe(Et)-C(O)OH,
—C(O)NMe-CH2—C(O)OH,
—C(O)NMe-CH2—C(O)OMe,
—C(O)NMe-CH2—C(O)OEt,
—C(O)NMe-CH2—C(O)OiPr,
—C(O)NMe-CH2—C(O)tBu,
—C(O)NMe-CH(Me)-C(O)OH,
C(O)—NH-5-tetrazolyl,
—O—SO2—C1-C5 alkyl),
—SO2(C1-C5 alkyl),
CH2S(O)2Me,
CH2S(O)2Et, and
CH2S(O)2iPr,
and a pharmaceutically acceptable salt thereof.
|